



April 7, 2017

To,

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Change in Directorate

Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held on 7th April, 2017 appointed Mr. Subesh Williams and Mr. Marc Jones and as Non-Executive Directors of the Company w.e.f April 7, 2017. We have enclosed brief profile of the Directors.

Thanking you,

Yours faithfully
For GlaxoSmithKline Pharmaceuticals Limited

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary



Brief profile of the Non-Executive Directors appointed from 7th April 2017

Subesh Williams

Subesh Williams is Senior Vice President, Global Corporate Development at GSK plc, a role he was appointed to in September 2013. In his current role, Subesh is responsible for M&A and Business Development across GSK's commercial businesses and has been involved in executing a number of transactions, including the creation of ViiV Healthcare (a HIV JV with Pfizer and Shionogi) and the 3 - part deal with Novartis which involved the acquisition of Novartis' vaccines business, the creation of a JV in Consumer Healthcare and the sale of GSK's oncology business. In 2016, Subesh was appointed to the Board of Galvani Bioelectronics a joint venture between GSK and Verily (a subsidiary of Alphabet). From 2009-2013, Subesh was Chief Financial Officer of ViiV Healthcare, with responsibility for Finance, Business Development, IT and Supply. Subesh joined GSK in 1994 and has had roles of increasing responsibility in Finance and Corporate Development. Subesh is a chartered accountant and, prior to joining GSK, was a manager at PwC. He does not hold any shares of the Company.

Marc Jones

Marc Jones joined GSK plc in March 2017 as Senior Vice President, Regional Pharma Supply. Marc joins GSK from AstraZeneca, where he has spent nearly thirty years, most recently leading Supply and Distribution for EMEA, with manufacturing in Sweden, UK, France, Germany, Egypt, Russia and Algeria. In his time at AstraZeneca, Marc has also led the supply organisation in Asia Pacific and Japan, based in Singapore, where he worked closely with commercial partners to build a strong presence in emerging markets and a low cost of goods footprint in China. At GSK plc, Marc will be leader of the Regional Pharma Supply organization, partnering with Local Operating Companies in all markets and driving GMS strategy and performance in regional manufacturing, External Supply and the Classic and Establish Products portfolio. He will also represent GMS on the Pharma Operating Committee. He does not hold any shares of the Company.

